Lv11
40 积分 2024-09-16 加入
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
5个月前
已完结
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
5个月前
已完结
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma
5个月前
已完结
Impact of Gene Mutations on Survival with Azacitidine or Conventional Care Regimens (CCR) in Older Patients with Acute Myeloid Leukemia
7个月前
已完结
Impact of Gene Mutations on Survival with Azacitidine or Conventional Care Regimens (CCR) in Older Patients with Acute Myeloid Leukemia
7个月前
已关闭
Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)
7个月前
已关闭
Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)
7个月前
已关闭
Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia
7个月前
已关闭
Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia
7个月前
已关闭
皖公网安备34019202002308
